Standout Papers

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma 2005 2026 2012 2019 4.4k
  1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma (2007)
    Robert J. Motzer, Thomas E. Hutson et al. New England Journal of Medicine
  2. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma (2007)
    Gary R. Hudes, Michael A. Carducci et al. New England Journal of Medicine
  3. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2008)
    Robert J. Motzer, Bernard Escudier et al. The Lancet
  4. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009)
    Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology
  5. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma (2005)
    Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology
  6. Phase 3 trial of everolimus for metastatic renal cell carcinoma (2010)
    Robert J. Motzer, Bernard Escudier et al. Cancer
  7. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease (2003)
    Nicolette Janzen, Hyung L. Kim et al. Urologic Clinics of North America
  8. Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System (2001)
    Amnon Zisman, Allan J. Pantuck et al. Journal of Clinical Oncology
  9. Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience (2005)
    Jean‐Jacques Patard, Emmanuelle Leray et al. Journal of Clinical Oncology
  10. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. (2003)
    Matthew Bui, David B. Seligson et al. PubMed
  11. Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib (2011)
    Brian I. Rini, Dongrui R. Lu et al. JNCI Journal of the National Cancer Institute

Immediate Impact

18 by Nobel laureates 9 from Science/Nature 158 standout
Sub-graph 1 of 15

Citing Papers

Renal Cell Carcinoma
2024 Standout
Renal cell carcinoma
2024 Standout
54 intermediate papers

Works of Robert A. Figlin being referenced

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
2023
Phase 3 trial of everolimus for metastatic renal cell carcinoma
2010 Standout
and 40 more

Author Peers

Author Last Decade Papers Cites
Robert A. Figlin 25082 21802 11928 467 37.4k
Bernard Escudier 26197 22473 14176 712 40.8k
Ronald M. Bukowski 19691 17507 13215 454 33.5k
Brian I. Rini 25164 19308 15310 761 37.4k
Stéphane Oudard 26909 16290 13527 611 37.9k
Toni K. Choueiri 24081 14617 17579 1.2k 40.4k
Robert J. Motzer 38543 30079 19079 921 57.3k
Walter M. Stadler 13822 11753 9239 466 26.3k
Roy S. Herbst 25944 16614 31201 573 49.6k
Tony Mok 38626 15477 34880 671 55.0k
Martin Gore 8895 12791 14140 377 29.0k

All Works

Loading papers...

Rankless by CCL
2026